Loading...
Loading...
BHVN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 1.0M |
| Gross Profit | -1.0M |
| Operating Expense | 332.8M |
| Operating I/L | -333.8M |
| Other Income/Expense | 14.2M |
| Interest Income | 0.0M |
| Pretax | -319.6M |
| Income Tax Expense | 0.2M |
| Net Income/Loss | -319.8M |
Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company focused on developing product candidates for neurological and neuropsychiatric diseases, and rare disorders in the United States. The company's flagship product, NURTEC ODT (rimegepant), is used for the acute treatment of migraine, with ongoing development for preventive treatment. Additionally, the company is developing Zavegepant for migraine and non-migraine indications, Troriluzole for various disorders including spinocerebellar ataxia and Alzheimer's disease, and BHV-0223 for amyotrophic lateral sclerosis. Biohaven also has a collaboration agreement with Cove to provide telemedicine evaluation for migraine sufferers.
